SAN FRANCISCO, Jan. 2, 2014 /PRNewswire/ -- iRhythm Technologies, a healthcare information services company, today announced that a prospective study by Scripps Translational Science Institute (STSI) has found that use of the company's ZIO Service significantly increased detection of cardiac arrhythmias, compared to use of the traditional Holter monitor. The findings, published and made publicly accessible online in the January issue of the American Journal of Medicine, underscore the role of the ZIO Service, comprised of the ZIO Patch, proprietary algorithms and ZIO Report, as the new standard for ambulatory monitoring of patients with suspected arrhythmia.
"This is the first large prospective validation that this new technology superseded the device invented by Norman Holter in 1949," said study senior author Eric Topol, M.D., a cardiologist who directs STSI and serves as the chief academic officer of Scripps Health. "By tracking every heart beat for up to two weeks, the ZIO Service proved to be significantly more sensitive than the standard Holter, which uses multiple wires and typically is only used or tolerated for 24 hours.
"For millions of people who present each year with suspected arrhythmia, this may prove to be the new standard for capturing the culprit heart rhythm electrical disturbance, most commonly atrial fibrillation which carries a significant risk of stroke," he said.
The prospective study included 146 consecutive Scripps Health patients who were referred for evaluation of cardiac arrhythmias and underwent simultaneous ambulatory ECG monitoring with a ZIO Patch, a patch worn on the chest, which continuously records heartbeats for up to 14 days, and a conventional 24-hour Holter monitor, a portable machine with multiple wires that connect to electrodes on the chest. Over the total wear time of both devices, the ZIO Service detected 57% more arrhythmia events compared to the Holter monitor (96 versus 61), primarily due to prolonged monitoring. Physicians also reported that they arrived at a definitive diagnosis in 90% of cases using the ZIO Service, compared to 64% with the Holter monitor. Further, 81% of patients reported they preferred the ZIO Patch versus the Holter monitor.
"Traditional cardiac monitoring options are limited in their ability to capture arrhythmias, which are infrequent and often have no symptoms, and because they are hard for patients to comply with," said Kevin King, iRhythm's president and chief executive officer. "These study findings underscore that the ZIO Service is setting a new standard for arrhythmia diagnosis, with a proven, long-term continuous monitoring approach that enables clinicians to rule in and rule out arrhythmias earlier in the diagnostic pathway and to change patient management."
Each year, millions of patients present with infrequent and non-specific symptoms such as heart palpitations, dizziness and shortness of breath, which may or may not be caused by cardiac arrhythmias. Reports estimate that the three most common types of arrhythmia—atrial fibrillation (AF), bradycardia and ventricular tachycardia—affect approximately 8 million people in the United States each year. If not treated properly, arrhythmias can lead to serious complications such as stroke. Effective management of cardiac arrhythmia is specific to the type of arrhythmia identified. Arrhythmias, however, are often difficult to diagnose using current monitoring techniques, which are limited in what they can record or can be difficult for patients to use or tolerate.
About the ZIO Service
The ZIO Service, comprised of the ZIO Patch, proprietary algorithms and the ZIO Report, is increasingly recognized as the new standard for ambulatory cardiac monitoring of patients with suspected arrhythmia. The ZIO Patch is a noninvasive, water-resistant monitor that is easy to use and discrete to wear, prompting high patient compliance and a higher diagnostic yield. Proprietary algorithms analyze the captured heart beat data and a concise report is provided to the patient's physician. Since its commercial launch in 2011, the ZIO Service has been used with more than 200,000 patients at nearly 800 institutions nationwide. The ZIO Service is covered for most Medicare patients and by leading private payers nationwide, representing more than 150 million covered lives.
About iRhythm Technologies, Inc.
iRhythm is a healthcare information services company that aspires to be the world leader in the management of cardiac arrhythmia information, a large and growing unmet clinical need. Its flagship solution, the ZIO Service, offers a proven approach to long-term continuous monitoring that enables diagnosis earlier in the clinical pathway to improve patient outcomes and reduce healthcare costs. For more information, please visit www.irhythmtech.com.
SOURCE iRhythm Technologies